Who is sponsoring NCT06463028?

NCT06463028 is sponsored by Faeth Therapeutics.

What condition does NCT06463028 study?

NCT06463028 studies Endometrial Cancer.

What drugs are being tested in NCT06463028?

Interventions: Sapanisertib, Serabelisib, Paclitaxel.

What is the status of NCT06463028?

NCT06463028 is currently RECRUITING.

Last reviewed 2025-12-22 · How we verify

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

NCT06463028 Phase 2 RECRUITING

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Details

Lead sponsor	Faeth Therapeutics
Phase	Phase 2
Status	RECRUITING
Enrolment	40
Start date	2024-12-12
Completion	2029-09

Conditions

Endometrial Cancer

Interventions

Sapanisertib
Serabelisib
Paclitaxel

Primary outcomes

Objective Response Rate (ORR) — Up to 2 years
Defined as the proportion of participants with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR).

Countries

United States